MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 16, 2009; DOI: 10.1124/mol.108.054411


0026-895X/09/7601-192-200$20.00
Mol Pharmacol 76:192-200, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.054411v1
76/1/192    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Li, T. W. H.
Right arrow Articles by Lu, S. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, T. W. H.
Right arrow Articles by Lu, S. C.

S-Adenosylmethionine and Methylthioadenosine Inhibit Cellular FLICE Inhibitory Protein Expression and Induce Apoptosis in Colon Cancer Cells

Tony W. H. Li, Qingsong Zhang, Pilsoo Oh, Meng Xia, Hui Chen, Sean Bemanian, Natalie Lastra, Magda Circ, Mary Pat Moyer, José M. Mato, Tak Yee Aw, and Shelly C. Lu

Division of Gastroenterology and Liver Diseases, University of Southern California Research Center for Liver Diseases, University of Southern California-University of California Los Angeles Research Center for Alcoholic Liver and Pancreatic Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California (T.W.H.L., Q.Z., P.O., M.X., H.C., S.B., N.L., S.C.L.); Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, Louisiana (M.C., T.Y.A.); and INCELL Corporation, San Antonio, Texas (M.P.M.); and CIC bioGUNE, Ciberehd, Bizkaia, Spain (J.M.M.)

S-Adenosylmethionine (SAMe) and its metabolite 5'-methylthioadenosine (MTA) inhibit mitogen-induced proliferative response in liver and colon cancer cells. SAMe and MTA are also proapoptotic in liver cancer cells by selectively inducing Bcl-xS expression. The aims of this work were to assess whether these agents are proapoptotic in colon cancer cells, and if so, to elucidate the molecular mechanisms. We found that both SAMe and MTA are proapoptotic in HT-29 and RKO cells in a dose- and time-dependent manner. Gene microarray uncovered down-regulation of cellular FLICE inhibitory protein (cFLIP). SAMe and MTA treatment led to a decrease in the mRNA and protein levels of both the long and short cFLIP isoforms. This required de novo RNA synthesis and was associated with activation of procaspase-8, Bid cleavage, and release of cytochrome c from the mitochondria. Inhibiting caspase 8 activity or overexpression of cFLIP protected against apoptosis, whereas supplementing with polyamines did not. SAMe and MTA treatment sensitized RKO cells to tumor necrosis factor {alpha}-related apoptosis-inducing ligand-induced apoptosis. Although SAMe and MTA are proapoptotic in colon cancer cells, they have no toxic effects in NCM460 cells, a normal colon epithelial cell line. In contrast to liver cancer cells, SAMe and MTA had no effect on Bcl-xS expression in colon cancer cells. In conclusion, SAMe and MTA are proapoptotic in colon cancer cells but not normal colon epithelial cells. One molecular mechanism identified is the inhibition of cFLIP expression. SAMe and MTA may be attractive agents in the chemoprevention and treatment of colon cancer.


Received for publication December 22, 2008.

Accepted for publication April 15, 2009.

Address correspondence to: Dr. Shelly C. Lu, Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, USC, HMR Bldg. 415, 2011 Zonal Ave., Los Angeles, CA 90033. E-mail: shellylu{at}usc.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics